Pharmaceuticals - Community Register

  

Community register of medicinal products for human use


AUTHORISED  

Product information

Invented name: Ryzodeg   
Auth. number : EU/1/12/806
INN : Insulin degludec/insulin aspart
ATC: Pending
Indication: Treatment of diabetes mellitus in adults
Marketing Authorisation Holder: Novo Nordisk A/S
Novo Allé, DK-2880 Bagsvaerd, Danmark

  EPAR and active package presentations

Package presentations

Information about presentations can be found in the website of the European Medicines Agency under the section "Product Information".
Likewise, presentations on which there has been a Commission decision are referred in the Summary of Product Characteristics (Annex I to the Commission Decision granting the marketing authorisation) which is available in the Community Register.

 

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
23/01/2013 Centralised - Authorisation EMEA/H/C/2499 (2013)368 of 21/01/2013
13/03/2013 Corrigendum (2013)1531 of 12/03/2013
06/05/2013 Centralised - Variation EMEA/H/C/2499/IAin/2
Updated with Decision(2014)2817 of 23/04/2014
06/05/2013 Centralised - Variation EMEA/H/C/2499/IAin/3
Updated with Decision(2014)2817 of 23/04/2014
20/11/2013 Centralised - Variation EMEA/H/C/2499/N/5
Updated with Decision(2014)2817 of 23/04/2014
20/12/2013 Centralised - Variation EMEA/H/C/2499/IAin/6/G
Updated with Decision(2014)2817 of 23/04/2014
03/02/2014 Centralised - Variation EMEA/H/C/2499/IA/8
Updated with Decision(2014)2817 of 23/04/2014
25/04/2014 Centralised - Variation (2014)2817 of 23/04/2014